Skip to main content

Pacritinib Side Effects

Medically reviewed by Drugs.com. Last updated on Oct 20, 2023.

Applies to pacritinib: oral capsule.

Serious side effects of Pacritinib

Along with its needed effects, pacritinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pacritinib:

More common

Less common

Incidence not known

Other side effects of Pacritinib

Some side effects of pacritinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to pacritinib: oral capsule.

General

The most commonly reported side effects included diarrhea, thrombocytopenia, and nausea.[Ref]

Cardiovascular

Very common (10% or more): Peripheral edema (up to 20%), serious hemorrhage (up to 13%)

Common (1% to 10%): Cardiac failure, fatal hemorrhage, QT prolongation

Frequency not reported: Arterial thrombosis, cardiovascular death, deep vein thrombosis, major adverse cardiac events (MACE), myocardial infarction, pulmonary embolism, thrombosis[Ref]

Dermatologic

Common (1% to 10%): Pruritus[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 48%), nausea (up to 32%), vomiting (up to 19%)[Ref]

Hematologic

Very common (10% or more): Thrombocytopenia (up to 34%), anemia (up to 24%)

Common (1% to 10%): Neutropenia[Ref]

Immunologic

Frequency not reported: Risk of infection (e.g., bacterial, fungal, mycobacterial, viral)[Ref]

Nervous system

Very common (10% or more): Dizziness (up to 15%)

Frequency not reported: Cerebral hemorrhage, meningorrhagia, stroke[Ref]

Ocular

Common (1% to 10%): Conjunctival hemorrhage[Ref]

Oncologic

Common (1% to 10%): Squamous cell carcinoma of skin

Frequency not reported: Acute myeloid leukemia, lymphoma, non-melanoma skin cancer (NMSC), secondary malignancies[Ref]

Other

Very common (10% or more): Pyrexia (up to 15%)

Common (1% to 10%): Disease progression

Frequency not reported: Multiorgan failure[Ref]

Respiratory

Very common (10% or more): Epistaxis (up to 12%)

Common (1% to 10%): Cough, dyspnea, pneumonia, upper respiratory tract infection[Ref]

References

1. Product Information. Vonjo (pacritinib). CTI BioPharma Corp. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.